Figures computed from official regulatory filings — .
Analysttarget 17.11 USD (+526%) · consensus 4.6/5 · 9 buy · 1 hold · 0 sell
Ownershipinsiders 0.42% · institutions 77.85% · short 26.6% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Altimmune, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
78 buys34 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Arbet-Engels Christophe | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Arbet-Engels Christophe | Other | $35K | SEC |
| Arbet-Engels Christophe | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MENZIUSO RICHARD THOMAS | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MENZIUSO RICHARD THOMAS | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Richardson Linda M | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Richardson Linda M | Other | $22.1K | SEC |
| Richardson Linda M | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Durso Jerome Benedict | Buy | $44.3K | conv 41 | SEC |
| Roberts M Scot | Award | $2.1K | SEC |
| WEAVER GREGORY Ltrack record | Award | $4.2K | SEC |
| Roberts M Scot | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Drutz David | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Drutz David | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Enright William | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Drutz David | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Redmont Venture Partners, Inc. | Award | n/a (No price was disclosed in the filing) | SEC |
| Schafer Klaus | Award | n/a (No price was disclosed in the filing) | SEC |
| Enright William | Award | n/a (No price was disclosed in the filing) | SEC |
| Tasker Sybil | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Drutz David | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Roberts M Scot | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Drutz David | Award | n/a (No price was disclosed in the filing) | SEC |
| Schafer Klaus | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Enright William | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |